TCR2 THERAPEUTICS INC.·4

Dec 20, 7:23 PM ET

Hofmeister Robert 4

4 · TCR2 THERAPEUTICS INC. · Filed Dec 20, 2019

Insider Transaction Report

Form 4
Period: 2019-12-19
Hofmeister Robert
Chief Scientific Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2019-12-19+50,00050,000 total
    Exercise: $16.10Exp: 2029-12-18Common Stock (50,000 underlying)
Holdings
  • Common Stock

    38,850
Footnotes (1)
  • [F1]25% of this option shall vest and become exercisable on January 1, 2021, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION